Review article

Nuclear medicine in the management of patients with heart failure: guidance from an expert panel of the International Atomic Energy Agency (IAEA)

Amalia Peix[b], Claudio Tinoco Mesquita[c], Diana Paez[a], Carlos Cunha Pereira[d], Renata Felix[e], Claudia Gutierrez[g], Rodrigo Jaimovich[i], Barbara Maria Ianni[f], Jose Soares Jr[f], Pastor Olaya[h], Ma. Victoria Rodriguez[j], Albert Flotats[k], Raffaele Giubbini[l], Mark Travin[m] and Ernest V. Garcia[n]

Heart failure is increasing worldwide at epidemic proportions, resulting in considerable disability, mortality, and increase in healthcare costs. Gated myocardial perfusion single photon emission computed tomography or PET imaging is the most prominent imaging modality capable of providing information on global and regional ventricular function, the presence of intraventricular synchronism, myocardial perfusion, and viability on the same test. In addition, ^{123}I-mIBG scintigraphy is the only imaging technique approved by various regulatory agencies able to provide information regarding the adrenergic function of the heart. Therefore, both myocardial perfusion and adrenergic imaging are useful tools in the workup and management of heart failure patients. This guide is intended to reinforce the information on the use of nuclear cardiology techniques for the assessment of heart failure and associated myocardial disease. *Nucl Med Commun* 35:818–823 © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Nuclear Medicine Communications 2014, 35:818–823

Introduction

Heart failure (HF) is growing globally at epidemic proportions, causing considerable increases in disability and mortality as well as in healthcare costs [1,2]. Coronary artery disease (CAD), diabetes mellitus, and hypertension are major etiological risk factors. HF affects more than 15 million people worldwide [2]. Dilated cardiomyopathy (DCM) refers to a heterogeneous spectrum of myocardial diseases that are characterized by ventricular dilation and reduced myocardial contractility. Once patients become symptomatic, the prognosis is relatively poor, with 25% mortality at 1 year and 50% mortality at 5 years [3]. Among the causes of acquired DCM in Latin America, Chagas cardiomyopathy is one of the most common, with a prevalence of ∼ 24 million [4] of HF in areas where the disease is endemic. Given the morbidity and mortality from HF, as well as the considerable resources that are used to diagnose and treat these patients, appropriate diagnosis and prognosis assessment are vital.

Gated myocardial perfusion ^{99m}Tc single photon emission computed tomography (SPECT) or PET imaging (MPI) is the most prominent imaging modality capable of providing, in a reproducible manner, information on global and regional ventricular function, the presence of intraventricular synchronism, myocardial perfusion, and viability on the same test. In addition, ^{123}I-mIBG scintigraphy is the only imaging technique approved by various regulatory agencies able to provide information regarding the adrenergic function of the heart. Therefore, both adrenergic imaging and MPI are useful tools in the workup and management of HF patients.

Results from a worldwide meta-analysis of all pertinent clinical trials up to 2007 suggest that ∼ 1–3% of all patients discharged alive after hospitalization for HF and

15–20% of all patients seen in HF clinics meet cardiac resynchronization therapy (CRT) eligibility criteria [5]; thus, all of these patients could be candidates for MPI dyssynchrony analysis. As about half of these numbers also meet the criteria for implantable cardiac defibrillator (ICD) implantation [5], it is also prudent to consider imaging these patients with ^{123}I-mIBG as an adjunct to their risk stratification for treatment selection. The specific number of HF patients who would benefit from undergoing these imaging techniques for a specific country is thus dependent on accurate statistics in terms of the total number of HF patients seen in clinics, which is a difficult number to obtain, depending on the country. It is estimated that HF affects 23 million people worldwide [6].

This guidance is a consensus statement from an international panel of nuclear medicine experts assembled by the International Atomic Energy Agency (IAEA). The initial purpose was to address how to use our techniques to help manage patients with Chagas disease, but the focus quickly transitioned to the topic of addressing the potential use of nuclear medicine techniques in all patients with HF. This guidance is intended to reinforce the information on the use of available nuclear cardiology techniques for the assessment of HF and associated myocardial disease. This article is not intended as an exhaustive review of all data on the subject of HF imaging but rather as a consensus statement of experts with knowledge on the existing evidence, mainly addressed to developing countries with limited resources. Because PET radiopharmaceuticals used in HF assessment are not widely available the panel focused on scintigraphic planar and SPECT procedures.

Why should a heart failure patient be sent for nuclear imaging?

The prevalence of heart failure is increasing in both developed and developing countries. Ischemic cardiomyopathy is the most common etiology of chronic HF [1]. The initial clinical management decision in HF patients is based on the differentiation of ischemic from nonischemic etiologies. Among a variety of diagnostic approaches including cardiac catheterization and several noninvasive imaging techniques, nuclear cardiology techniques such as MPI and ^{123}I-mIBG imaging have an important role in the diagnostic workup and risk assessment of patients with HF.

Myocardial perfusion imaging

Recent recommendations [7] and appropriate use criteria state that nuclear cardiology techniques are adequate in patients with new-onset or newly diagnosed HF [8]. The main indication for MPI in the HF population is for the identification of patients who may benefit from therapy for myocardial ischemia and ventricular dysfunction,

which includes medical treatment, revascularization, and resynchronization devices.

Cardiac resynchronization therapy

CRT is a biventricular pacemaker with a third electrode attached to the left ventricle to assist in resynchronizing the mechanical contraction of the left ventricular (LV). CRT has been shown to benefit some patients with end-stage HF, depressed left ventricular ejection fraction (LVEF) (< 35%), and a wide QRS complex on the surface ECG (>120 ms [9] or even > 150 ms [10]), and is now standard treatment for HF [10]. As electrical activation is often decoupled from the onset of mechanical contraction, the main indication for MPI in patients being considered for CRT is for the identification of LV mechanical dyssynchrony and for guiding the placement of the LV lead to the last viable contracting segment for optimal response (improvement of LV function) [11].

The specific reasons why a patient with heart failure should be referred to nuclear cardiology myocardial perfusion imaging:

(1) To assess myocardial ischemia.
(2) To assess LV global and regional viability.
(3) To assess whether LV function is preserved, including regional wall motion and thickening, LVEF, LV volumes, and myocardial LV mass.
(4) To assess LV eccentricity [12].
(5) To assess LV intraventricular dyssynchrony [13,14].
(6) To assess the last viable segment to contract in patients being considered for CRT [15].

In addition, assessing patients' risk of cardiac death contributes to the determination of the probability of sudden death and the need for an ICD [16].

[123]I-mIBG imaging

Much evidence has accumulated to show that cardiac autonomic imaging, such as with ^{123}I-mIBG, is a powerful risk stratification tool for patients with HF [17]. In the setting of this condition, normal autonomic balance is disrupted, which is not only evidence of the severity of the condition but also an indicator of a worsening prognosis [17,18]. With ^{123}I-mIBG imaging, which is based on a false transmitter analog of norepinephrine, we can assess cardiac sympathetic innervation.

On the basis of worldwide experience, the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology have recently proposed standardized methods [19], but more work needs to be done in this regard. The ideal imaging procedures, including patient preparation, medication holding, dosage of tracer, acquisition protocols, and quantitative methods, are evolving [20]. At this time, planar ^{123}I-mIBG imaging procedures

are well established, although more work is needed for SPECT imaging and comparative analysis with MPI.

[123]I-mIBG availability is severely limited throughout the world, being actively used only in specific regions. Although available in Japan, Europe, and Brazil for a long time, ^{123}I-mIBG has just been recently approved in the USA by the FDA for HF evaluation.

Multiple studies have shown that ^{123}I-mIBG imaging, especially determination of the heart-to-mediastinum (H/M) ratio, very effectively separates high-risk from low-risk patients, regardless of LVEF and NYHA clinical conditions [17,21]. In fact, patients with a normal H/M ratio have an excellent prognosis despite other abnormal cardiac parameters, such as LVEF and brain natriuretic peptide, and on multivariate analysis H/M has consistently been shown to provide independent incremental risk stratification power [17,21]. However, risk stratification is useful only to the extent that it allows guidance of therapies that would improve patient outcome and well-being.

The specific reasons why a patient with heart failure should be referred to nuclear cardiology ^{123}I-mIBG:

(1) To assess ^{123}I-mIBG cardiac uptake as given by the H/M ratio [18].
(2) To use the H/M ratio to help risk stratify the patient [21].
(3) To use the H/M ratio in risk stratification to help decide on a change of management decision. For example, the condition of an HF patient without ICD has changed and now ICD is being considered [22].

Radiation burden
Concerns about medical exposure to ionizing radiation in cardiac patients have become heightened in recent years as a result of rapid growth in procedure volumes and the high radiation doses incurred from some procedures. Although several landmark epidemiological studies involving similar levels of radiation exposure show increased cancer risk, no strong data currently relate ionizing radiation specifically from cardiac imaging to increased risks of cancer [23]. Important benefits of cardiac imaging for adequate patient management, such as correct diagnosis, accurate prognostication, and improvement of outcomes, should also be taken into account.

In general, radiation dose is less of a concern in elderly patients with HF because the risk of dying from heart disease is far greater than any radiation concern. Patients admitted to hospital with a diagnosis of cancer often have a longer survival compared with those with a diagnosis of HF. Prognosis in HF that requires hospitalization can be considered far worse than that of many common types of cancer. For example, in the Framingham cohort, 62 and

75% of men and 38 and 42% of women, respectively, died within 5 years of being diagnosed with HF [24]. In comparison, 5-year survival rate from all cancers among men and women in the USA during the same period was ~ 50% [24].

Regardless, the least amount of radiation burden for the patient should always be taken into account for each specific protocol.

Because of the higher radiation exposure to the patient from thallium-201, if other tracers are available they should be considered as alternatives, although the effective dose (mSv/MBq) has been revised and lowered by one-third from $2.1E - 01$ to $1.4E - 01$ [25].

Complementary techniques
Other noninvasive imaging techniques such as echocardiography, computed tomography, and MRI can provide useful information for both diagnostic and prognostic purposes in HF patients.

Echocardiography
Transthoracic echocardiography remains the most performed myocardial imaging technique because of its widespread availability, low cost, and ability to provide information on valvular function, atrial size, right ventricular size, and contractility. Stress echocardiography, either with physical stress or with dobutamine, is extensively used to noninvasively detect the presence of CAD, the most common underlying etiology of DCM. In contrast, tissue Doppler imaging techniques [26,27] or, more recently, speckle-tracking echocardiography has been used to provide information on LV dyssynchrony before CRT, as well as to help in the prediction of response to this therapy [28,29]. Echocardiography is the first imaging test recommended in the ACC/AHA guidelines [30,31] and in the ESC guidelines for the diagnosis of LV systolic dysfunction [32].

However, it is important to point out the need for acceptable echocardiographic windows to precisely determine these parameters, as well as to emphasize that the technique is less reproducible than nuclear cardiology techniques, requiring a considerable level of expertise of the echocardiographer.

Coronary computed tomography
Coronary computed tomographic angiogram (CCTA) allows the noninvasive visualization of coronary anatomy and helps to define plaque morphology. It is currently considered a well-established tool for evaluating coronary disease [33,34]. The main strength of CCTA seems to be the reliable exclusion of atherosclerotic disease because of its very high negative predictive value, which is particularly important in patients with intermediate-to-low CAD pretest probability. Thus, CCTA could be a useful

tool in excluding CAD as the likely culprit for LV systolic dysfunction in this setting.

Coronary calcium evaluation is a useful way to non-invasively assess atherosclerotic burden and provides some guidance to the clinician for the differential diagnosis between a possible ischemic versus nonischemic etiology for LV systolic dysfunction [35]. Nevertheless, further studies with larger series of patients are needed to establish its role in this group of patients.

It is important to point out that the information offered by CCTA is mainly anatomical and does not include data regarding the presence or absence of ischemia, which is of particular interest in case of patients with CAD who need a revascularization procedure. Nuclear techniques are very well standardized in this setting, offering valuable information on the presence and extension of ischemia, as well as on the status of the intraventricular synchronization, very useful in the case of patients evaluated for CRT.

Cardiac magnetic resonance
Cardiac magnetic resonance (CMR) is a versatile tool used to assess etiology in congestive heart failure because of its capability for tissue characterization and simultaneous assessment of LV function and wall motion and the possibility of myocardial viability detection through the late enhancement gadolinium images, which accurately delineate a scar, a powerful marker of poor prognosis in DCM. CMR has the advantage of not using ionizing radiation. The American College of Cardiology and the American College of Radiology have recommended CMR as an appropriate tool for the evaluation of LV systolic dysfunction of unknown etiology [36]. However, it is a very expensive technique that is not broadly available in cardiac services, contrary to the already established nuclear techniques.

Key points
On the basis of the current available evidence, the following points represent our consensus position for guidance on the use of nuclear cardiology techniques for the assessment of HF and associated myocardial disease:

(1) To assess ischemia, a 1- or 2-day rest–stress protocol probably with pharmacologic stress and nitrates for rest should be used. Assessment of viability is important and should include assessment of scar burden. Scar burden is defined by the total amount of scar in the LV expressed as a percentage of the total LV and is an independent prognostic factor as well as a variable for treatment choice. If ^{18}F-FDG is available for viability assessment it should be used, but in most situations an adequate SPECT MPI can provide the necessary information.

(2) In HF patients, gating to help measure function is very important, although these patients have more gating problems [37]. Only a nongated MPI should be acquired in patients with atrial fibrillation if rejection of bad beats is not possible. QC of the R wave triggering is important. If possible use the R-R window to reject bad beats. Availability of backward gating will also improve the accuracy of assessment of the diastolic parameters.

(3) Physicians should be aware of the differences in normal values for the functional parameters of the software being used. Specifically, the report should include assessment of LVEF, LV end-systolic volume, transient ischemic dilation, eccentricity, and LV dyssynchrony. In addition, in patients being assessed for CRT the report should also include the last viable segment to contract (Tables 1 and 2).

(4) LV synchrony assessment is important, particularly for patients being considered for CRT therapy [13,14]. LV synchrony may be assessed with either the rest or the stress study, preferably using the study with the most counts [27]. Synchrony should be similar for the poststress and rest study if the stress acquisition is performed at least 1 h after stress [38]. However, if image acquisition is performed closer to stress then differences in synchrony can be found in CAD patients [39,40]. Gating should be done with either 8 or 16 frames per cardiac cycle. All acquisition parameters used should be the same as standard MPI acquisition [7]. In processing, care must be taken to QC the selection of the base throughout the cardiac cycle as improper selection will lead to measurement errors. The processing software used should have been validated for the synchrony parameters used for evaluation. At this time the SD and histogram bandwidth of the LV phase histogram have been shown to be useful in determining dyssynchrony [13,14].

(5) It has been shown that 71% of HF patients who fulfill the CRT criteria respond to the treatment if their bandwidth is greater than 135° and/or SD is greater than 43° [41]. It has also been reported that just having this amount of dyssynchrony is not enough for a patient to have a positive response to CRT [17]. The following is also important to assure a higher probability of success to therapy: (i) the patient should have less than 50% of scar burden [42], and

Table 1 Perfusion parameters that should be reported in myocardial perfusion imaging studies of heart failure patients

Parameters	Format
Ischemia and viability	% from total LV myocardium and location
Scar/necrosis	% from total LV myocardium and location
Viability[a]	More than 50% uptake from maximum wall uptake

LV, left ventricular.
[a]If ^{18}F-FDG is used, mismatch criteria for viability should be considered [6].

Table 2 Functional parameters that should be reported in myocardial perfusion imaging studies of heart failure patients

Parameters	Format
Volumes and shape	ESV, LVEF, TID, eccentricity
Wall motion and thickening	Segmental motility and thickening
Synchronicity	LV dyssynchrony (phase BW and phase SD)
Lead placement orientation	Last viable segment to contract

BW, bandwidth; ESV, end-systolic volume; LV, left ventricular; LVEF, left ventricular ejection fraction; TID, transient ischemic dilation.

Table 3 Parameters that should be reported in heart failure patients ^{123}I-mIBG studies

Parameters	Format
Global cardiac innervation	Delayed H/M ratio
Sympathetic tone	Washout rate
Regional denervation	Semiquantitative assessment of uptake and location

H/M, heart-to-mediastinum ratio.

(ii) the LV lead should be placed (if technically possible) in the last viable segment to contract.

(6) Segmental time of onset of contraction may be evaluated either visually from dynamic phase displays or preferably through segmental phase histogram measurements.

(7) Planar gated blood pool images have also been used for assessment of dyssynchrony [43–45]. The advantage of this approach is that interventricular dyssynchrony can also be assessed, but the disadvantage is that it is a volumetric approach but not three dimensional. This limitation may be corrected with SPECT techniques of blood pool imaging, which are inherently three dimensional.

(8) Echocardiography is another option for evaluating LV dyssynchrony, particularly using the appropriate software (three-dimensional speckle tracking) [29,46].

(9) ^{123}I-mIBG is commonly imaged in an anterior planar view initially (15–30 min after injection) and in delayed images 4 h later, and optionally with SPECT imaging [19]. Global cardiac uptake is expressed as H/M ratio on the delayed images. With current imaging methods bad prognosis in HF patients is observed when H/M ratio is under 1.6 in delayed images; normal values are above this cutoff (Table 3). Tracer washout between initial and 4 h delayed images may also be measured, as well as the extent and severity of regional defect(s) on delayed tomographic imaging.

Acknowledgements

Conflicts of interest
Ernest V. Garcia receives royalties from the sale of the Emory Cardiac Toolbox with SyncTools and AdreviewTools. Dr Garcia also received grant funding from GE Healthcare for the development of MIBG SPECT software (AdreviewTools). He also owns shares of Syntermed Inc. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict-of-interest practice. Dr Mark I. Travin is a consultant to, and has received grant funding from GE Healthcare. Most of the authors were funded by the IAEA as consultants and to travel to a meeting for writing this guidance document

References
1 Cubillos-Garzon LA, Casas JP, Morillo CA, Bautista LE. Congestive heart failure in Latin America: the next epidemic. *Am Heart J* 2004; **147**:412–417.
2 Najafi F, Jamrozik K, Dobson AJ. Understanding the 'epidemic of heart failure': a systematic review of trends in determinants of heart failure. *Eur J Heart Fail* 2009; **11**:472–479.
3 Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. *JAMA* 2011; **306**:1669–1678.
4 Bocchi EA. Heart failure in South America. *Curr Cardiol Rev* 2013; **9**:147–156.
5 McAlister FA, Ezekowitz J, Dryden DM, Hooton N, Vandermeer B, Friesen C, *et al.* Cardiac resynchronization therapy and implantable cardiac defibrillators in left ventricular systolic dysfunction. *Evid Rep Technol Assess (Full Rep)* 2007; **152**:1–199.
6 Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A. Worldwide risk factors for heart failure: a systematic review and pooled analysis. *Int J Cardiol* 2013; **168**:1186–1194.
7 International Atomic Energy Agency (IAEA). *Nuclear Cardiology: guidance and recommendations for implementation in developing countries. IAEA Human Health Series No. 23 STI/PUB/1566.* Vienna, Austria: IAEA; 2012.
8 Hendel RC, Berman DS, Di Carli MF, Heidenreich PA, Henkin RE, Pellikka PA, *et al.* ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. *J Am Coll Cardiol* 2009; **53**:2201–2229.
9 Leclercq C, Kass DA. Retiming the failing heart: principles and current clinical status of cardiac resynchronization. *J Am Coll Cardiol* 2002; **39**:194–201.
10 Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA III, Freedman RA, Gettes LS, *et al.* American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Heart Rhythm Society 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Circulation* 2013; **127**:e283–e352.
11 Donal E, de Chillou C, Magnin-Poull I, Leclercq C. Imaging in cardiac resynchronization therapy: what does the clinician need? *Europace* 2008; **10 (Suppl 3)**:iii70–iii72.
12 Germano G, Slomka P, Berman D. Computer aspects of myocardial imaging. In: Henkin R, editor. *Nuclear medicine.* 2nd ed. Philadelphia: Elsevier; 2006. pp. 609–630.
13 Chen J, Henneman M, Trimble M, Bax J, Borges-Neto S, Iskandrian A, *et al.* Assessment of left ventricular mechanical dyssynchrony by phase analysis of ECG-gated SPECT myocardial perfusion imaging. *J Nucl Cardiol* 2008; **15**:127–131.

14   Chen J, Garcia EV, Bax J, Iskandrian A, Borges-Neto S, Prem S. SPECT myocardial perfusion imaging for the assessment of left ventricular mechanical dyssynchrony. *J Nucl Cardiol* 2011; **18**:685–694.

15   Boogers MJ, Chen J, van Bommel RJ, Borleffs CJ, Dibbets-Schneider P, van der Hiel B, *et al.* Optimal left ventricular lead position assessed with phase analysis on gated myocardial perfusion SPECT. *Eur J Nucl Med Mol Imaging* 2011; **38**:230–238.

16   Aljaroudi WA, Hage FG, Hermann D, Doppalapudi H, Venkataraman R, Heo J, *et al.* Relation of left-ventricular dyssynchrony by phase analysis of gated SPECT images and cardiovascular events in patients with implantable cardiac defibrillators. *J Nucl Cardiol* 2010; **17**:398–404.

17   Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial ^{123}I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. *Eur Heart J* 2008; **29**:1147–1159.

18   Travin MI. Cardiac autonomic imaging with SPECT tracers. *J Nucl Cardiol* 2013; **20**:128–143.

19   Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, *et al.* EANM Cardiovascular Committee. European Council of Nuclear Cardiology. Proposal for standardization of ^{123}I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. *Eur J Nucl Med Mol Imaging* 2010; **37**:1802–1812.

20   Chen J, Folks RD, Verdes L, Manatunga DN, Jacobson AF, Garcia EV. Quantitative I-123 mIBG SPECT in differentiating abnormal and normal mIBG myocardial uptake. *J Nucl Cardiol* 2012; **19**:92–99.

21   Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, *et al.* ADMIRE-HF Investigators. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. *J Am Coll Cardiol* 2010; **55**:2212–2221.

22   Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, *et al.* Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. *J Am Coll Cardiol* 2010; **55**:2769–2777.

23   Einstein AJ. Effects of radiation exposure from cardiac imaging: how good are the data? *J Am Coll Cardiol* 2012; **59**:553–565.

24   Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation* 1993; **88**:107–115.

25   ICRP. Radiation dose to patients from radiopharmaceuticals, ICRP Publication 106. *Ann ICRP* 2008; **38**:159–162.

26   Bax JJ, Abraham T, Barold SS, Breithardt OA, Fung JW, Garrigue S, *et al.* Cardiac resynchronization therapy: part 1 – issues before device implantation. *J Am Coll Cardiol* 2005; **46**:2153–2167.

27   Godoy IE, Mor-Avi V, Weinert L, Vignon P, Korcarz C, Spencer KT, Lang RM. Use of color kinesis for evaluation of left ventricular filling in patients with dilated cardiomyopathy and mitral regurgitation. *J Am Coll Cardiol* 1998; **31**:1598–1606.

28   Suffoletto MS, Dohi K, Cannesson M, Saba S, Gorcsan J III. Novel speckle-tracking radial strain from routine black-and-white echocardiographic images to quantify dyssynchrony and predict response to cardiac resynchronization therapy. *Circulation* 2006; **113**:960–968.

29   Tanaka H, Nesser HJ, Buck T, Oyenuga O, Janosi R, Winter S, *et al.* Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study. *Eur Heart J* 2010; **31**:1690–1700.

30   American Heart Association. American Heart Association Heart and Stroke Statistics, 2004. Available at: *http://www.americanheart.org*. [Accessed 21 August 2006].

31   Hunt S. ACC/AHA guideline update for CHF. *J Am Coll Cardiol* 2005; **46**: e1–e82.

32   Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, *et al.* Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. *Eur Heart J* 2005; **26**:1115–1140.

33   Leber AW, Knez A, von Ziegler F, Becker A, Nikolaou K, Paul S, *et al.* Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography: a comparative study with quantitative coronary angiography and intravascular ultrasound. *J Am Coll Cardiol* 2005; **46**:147–154.

34   Raff GL, Gallagher MJ, O'Neill WW, Goldstein JA. Diagnostic accuracy of noninvasive coronary angiography using 64-slice spiral computed tomography. *J Am Coll Cardiol* 2005; **46**:552–557.

35   Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, *et al.* American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography); Society of Atherosclerosis Imaging and Prevention; Society of Cardiovascular Computed Tomography. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. *J Am Coll Cardiol* 2007; **49**:378–402.

36   Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, *et al.* ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. *Circulation* 2010; **121**:2462–2508.

37   Ludwig DR, Friehling M, Schwartzman D, Saba S, Follansbee WP, Soman P. On the importance of image gating for the assay of left ventricular mechanical dyssynchrony using SPECT. *J Nucl Med* 2012; **53**:1892–1896.

38   Aljaroudi W, Koneru J, Heo J, Iskandrian AE. Impact of ischemia on left ventricular dyssynchrony by phase analysis of gated single photon emission computed tomography myocardial perfusion imaging. *J Nucl Cardiol* 2011; **18**:36–42.

39   Chen CC, Shen TY, Chang MC, Hung GU, Chen WC, Kao CH, Chen J, *et al.* Stress-induced myocardial ischemia is associated with early post-stress left ventricular mechanical dyssynchrony as assessed by phase analysis of ^{201}Tl gated SPECT myocardial perfusion imaging. *Eur J Nucl Med Mol Imaging* 2012; **39**:1904–1909.

40   Al Jaroudi W, Alraies MC, Menon V, Brunken RC, Cerqueira MD, Jaber WA. Predictors and incremental prognostic value of left ventricular mechanical dyssynchrony response during stress-gated positron emission tomography in patients with ischemic cardiomyopathy. *J Nucl Cardiol* 2012; **19**:958–969.

41   Henneman MM, Chen J, Dibbets-Schneider P, Stokkel MP, Bleeker GB, Ypenburg C, *et al.* Can LV dyssynchrony as assessed with phase analysis on gated myocardial perfusion SPECT predict response to CRT? *J Nucl Med* 2007; **48**:1104–1111.

42   Bleeker GB, Kaandorp TA, Lamb HJ, Boersma E, Steendijk P, de Roos A, *et al.* Effect of postero-lateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. *Circulation* 2006; **113**:969–976.

43   Kerwin WF, Botvinick EH, O'Connell JW, Merrick SH, DeMarco T, Chatterjee K, *et al.* Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct inter-ventricular dyssynchrony. *J Am Coll Cardiol* 2000; **35**:1221–1227.

44   Fauchier L, Marie O, Casset-Senon D, Babuty D, Cosnay P, Fauchier JP. Interventricular and intra-ventricular dyssynchrony in idiopathic dilated cardiomyopathy: a prognostic study with Fourier phase analysis of radionuclide angioscintigraphy. *J Am Coll Cardiol* 2002; **40**:2022–2030.

45   Toussaint JF, Lavergne T, Kerrou K, Froissart M, Ollitrault J, Darondel JM, *et al.* Basal asynchrony and resynchronization with biventricular pacing predict long-term improvement of LV function in heart failure patients. *Pacing Clin Electrophysiol* 2003; **26**:1815–1823.

46   Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O'Halloran D, Elsik M, *et al.* Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. *J Am Coll Cardiol* 2012; **59**:1509–1518.